Aveed (Testosterone Undecanoate) Patent Expiration, LOE Window & CMS Spending

Aveed (Testosterone Undecanoate) by Endo Pharmaceuticals: FDA Orange Book LOE 2027-05-08, 0 AB generics, $3.3M 2024 CMS Part D & Medicaid spend, and 7 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEndo Pharmaceuticals
FDA Application & PathwayN022219 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-05-08
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.3M
2024 Medicare Part D Spend$1.6M
2024 Medicaid Spend$1.7M
Reported Wholesale Price Change (CA SB 17)7 WAC filings (max 33.1% 2-yr change)